Thrusting Cambridge biopharma business Arecor is planning a UK IPO. The company is advancing a robust portfolio of partnered and proprietary treatments from existing therapies to enable healthier lives. Diabetes is a prime area.
Arecor set for UK IPO
Tony Quested of Business Weekly writes:
Arecor CEO Sarah Howell said the IPO would enable the company to advance the development of its internal proprietary diabetes and specialty hospital products to a defined value inflexion point prior to potential partnering.
Business Weekly is an independently owned newspaper founded in May 1990 to fill a void in the B2B media marketplace.